A Two Part, Multicenter Phase IIa, Placebo Controlled Study, to Examine the Safety, Tolerability, and Effects of GSK256073 on Lipids in Subjects With Dyslipidemia.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs GSK 256073; Niacin
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Apr 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Actual patient number (81) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.